Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Charles River Laboratories (CRL)

Charles River Laboratories Reports Third-Quarter 2026 Results and Raises Guidance

Positive Impact 4 of 5 earnings

Charles River Laboratories International reported third-quarter 2026 revenue of $982.7 million and increased its full-year guidance for revenue and non-GAAP earnings per share. The results were driven by a 4.7% increase in organic revenue and a lower tax rate, alongside a significant benefit from the reversal of acquired tax reserves.

Key points

  • Third-quarter revenue reached $982.7 million, with organic revenue growing 4.7% year-over-year.
  • GAAP earnings per share were $6.86 and non-GAAP earnings per share were $3.09 for the quarter ended September 26, 2026.
  • Full-year 2026 GAAP EPS estimate was updated to $8.15 to $8.35 and non-GAAP EPS estimate to $11.35 to $11.55.

The filing

CompanyCharles River Laboratories (CRL)
Form8-K, current report
Filed with the SECNov 4, 2026, 7:04 AM ET
Accession number0001100682-26-000156

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Google Gemini, gemini-3.5-flash-lite) on Nov 4, 2026, 8:16 AM ET, from the text of the filing and its press-release exhibits only.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.